Novoprotein(SH:688137) Zhong Guo Jing Ji Wang·2025-03-02 08:00Group 1 - The company Nearshore Protein (688137.SH) reported a total operating revenue of 127.447 million yuan for the fiscal year 2024, a year-on-year decrease of 16.81% [1] - The net profit attributable to the parent company was -54.807 million yuan, compared to a profit of 12.8436 million yuan in the previous year, representing a year-on-year decline of 526.72% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was -72.2141 million yuan, compared to -7.2106 million yuan in the previous year [1] Group 2 - Nearshore Protein was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on September 29, 2022, with an issue price of 106.19 yuan per share and a total of 17.54386 million shares issued [1] - The company is currently in a state of stock price decline, having broken its initial offering price [1] - The total amount raised from the initial public offering was 1.8629825 billion yuan, with a net amount of 1.7421958 billion yuan after deducting issuance costs, which was 242.1958 million yuan more than originally planned [1] - The funds raised are intended for projects related to the industrialization of core diagnostic materials and innovative diagnostic reagents, the construction of a research and development center, and to supplement working capital [1] Group 3 - The total issuance costs for the initial public offering amounted to 120.7867 million yuan, with the underwriting and sponsorship fees for the sponsor, Minsheng Securities Co., Ltd., being 98.4217 million yuan [2]